Morfina Kalceks (Morphine Hydrochloride)

• Morphine, an opioid analgesic, relieves pain by activating central mu‑opioid receptors.
• Severe acute pain: provides rapid relief of intense pain episodes.
• Postoperative pain: reduces discomfort following surgical procedures.
• Cancer pain: manages chronic pain associated with malignant disease.
• Severe chronic non‑cancer pain: offers long‑term analgesia when alternative therapies are inadequate.
• Palliative care: improves quality of life by controlling distressing pain in end‑of‑life settings.

• Morphine binds to and activates mu‑opioid receptors in the central nervous system, inhibiting the release of excitatory neurotransmitters and reducing neuronal excitability. This action decreases the perception of pain, alters pain‑related emotional responses, and produces analgesia. The drug also modulates descending pain pathways, contributing to its overall effect on nociceptive signaling.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset often occurring shortly after administration.
• Constipation: reduced bowel motility leading to hard stools.
• Drowsiness or sedation: decreased alertness and increased sleepiness.
• Dizziness or light‑headedness: sensation of imbalance or faintness.
• Sweating: excessive perspiration unrelated to temperature.
• Dry mouth: reduced salivary flow causing oral discomfort.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure causing faintness or shock.
• Anaphylactic reaction: sudden, severe allergic response with rash, swelling, and airway compromise.
• Adrenal insufficiency: impaired cortisol production leading to fatigue and weakness.
• Seizures (rare): uncontrolled electrical activity in the brain.

When using Morfina Kalceks, clinicians should consider several safety measures.

• Assess pain severity: ensure opioid therapy is appropriate for the intensity of pain.
• Monitor respiratory function: watch for signs of slowed breathing, especially after dose adjustments.
• Adjust dose in renal or hepatic impairment: reduce dosage or increase monitoring in patients with organ dysfunction.
• Avoid concurrent CNS depressants: limit use with benzodiazepines, alcohol, or other sedatives.
• Use caution in pregnancy: weigh benefits against potential fetal risks; category C.
• Store at controlled room temperature: keep in original container, protect from moisture and light.

Morphine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other opioids: additive respiratory depression and sedation.
• Central nervous system depressants (e.g., benzodiazepines): heightened risk of profound sedation.
• Monoamine oxidase inhibitors (MAOIs): can precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may increase morphine plasma levels.
• Diuretics: can enhance hypotensive effects when combined with morphine.